Source: CureToday articles
Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years.
Recent Content
- Maximizing RRMM strategy time at doctor appointments
- Don’t underestimate organization’s importance in RRMM care
- Embrace the toughest RRMM conversations ASAP
- A lay of the land in evolving RRMM treatment options
- CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target
- New registry aims to support research for pediatric acute myeloid leukemia
- Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium
- Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia
- Efficacy and safety profile of busulfan plus low dose melphalan (BUMEL) versus high dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cells transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis
- New AI-based tool aims to help guide treatment for pancreatic cancer